Drug safety profile of integrase strand transfer inhibitors.

Item

http://www.wikidata.org/entity/Q38193524

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Drug safety profile of integrase strand transfer inhibitors.

@en

type

Item

label

Drug safety profile of integrase strand transfer inhibitors.

@en

prefLabel

Drug safety profile of integrase strand transfer inhibitors.

@en

P1476

Drug safety profile of integrase strand transfer inhibitors

@en

P2093

Maria Gracia Mateo

http://www.w3.org/2001/XMLSchema#string

Maria del Mar Gutierrez

http://www.w3.org/2001/XMLSchema#string

Pere Domingo

http://www.w3.org/2001/XMLSchema#string

P2860

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Raltegravir with optimized background therapy for resistant HIV-1 infection

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.

Integrase inhibitors to treat HIV/AIDS.

Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial

Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.

Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study

Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy.

The future of integrase inhibitors of HIV-1.

P304

431-445

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.2014.897327

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Francesc Vidal

P577

2014-03-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260561424

http://www.w3.org/2001/XMLSchema#string

P698

24597519

http://www.w3.org/2001/XMLSchema#string